New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
05:55 EDTLLY, LLY, LLY, DNA, DNA, DNA, BMY, BMY, BMY, PFE, PFE, PFE, RHHBY, RHHBY, RHHBY, BIIB, BIIB, BIIB, JAZZ, JAZZ, JAZZ, SNY, SNY, SNY, GILD, GILD, GILD, CORT, CORT, CORT, HZNP, HZNP, HZNPDrug Information Association to host a forum
Medical & Scientific Communications 2013 Annual Forum is being held in Chandler, Arizona on March 19-21.
News For LLY;CORT;GILD;SNY;JAZZ;BIIB;RHHBY;PFE;BMY;DNA;HZNP From The Last 14 Days
Check below for free stories on LLY;CORT;GILD;SNY;JAZZ;BIIB;RHHBY;PFE;BMY;DNA;HZNP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 17, 2013
13:21 EDTBMYOptions with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information
08:03 EDTSNYSanofi reports positive topline results from pivotal Phase III Jakarta study
Subscribe for More Information
05:18 EDTSNYSanofi says JAK2 inhibitor for myelofibrosis met primary endpoint
Subscribe for More Information
May 16, 2013
16:32 EDTBMYBristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information
13:20 EDTBMYFollow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares.
13:14 EDTBMYBristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information
11:50 EDTGILDCelgene, Gilead lower after new data published at ASCO
Subscribe for More Information
08:55 EDTBMY, PFE, LLYBofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information
08:38 EDTBMYBristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers.
07:29 EDTBIIBLeerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17.
05:52 EDTBMYStocks with implied volatility movement; BMY SLV
Subscribe for More Information
May 15, 2013
18:32 EDTGILDGilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information
15:59 EDTRHHBYRoche exploring sale of blood glucose meters unit, Reuters says
Subscribe for More Information
15:16 EDTSNYSanofi systemic sclerosis treatment designated for orphan drug status
Subscribe for More Information
12:13 EDTRHHBYRoche management to meet with Jefferies
Meeting to be held in London on May 17 hosted by Jefferies.
11:38 EDTRHHBYRoche says FDA approves Tarceva tablets for specific lung cancer situation
Subscribe for More Information
11:28 EDTBMYOptions with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information
09:43 EDTBMYActive equity option families trading on open
Subscribe for More Information
05:39 EDTSNYSanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information
May 14, 2013
16:55 EDTRHHBYFDA approves Roche's cobas EGFR mutation test with Tarceva
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.